March 16, 2010
Posted by on
Health Canada released the finalized version of its Guidance Document for “Subsequent Entry Biologics” (SEBs). The final version is mostly the same as the draft guidance released last March, and actually comes after the approval of Canada’s first SEB last April.
SEBs are a class of drugs that the EU calls “biosimilars” and the U.S. calls “a class of biologics we may recognize one day if health reform passes”“follow-on biologics,” but the gist is that they are copycat versions of existing large-molecule drugs. Because of their complexity, different versions of the same biologic cannot be characterized as identical. Hence “similar”.
Regulators are seeking a balance with respect to how much biosimilars can rely on data from the original (“reference”) drug in applying for their own approval, and with respect to how long to protect the reference drug’s data. Here are some highlights of Health Canada’s approach:
- A full New Drug Submission required for SEBs, (not an abbreviated submission, as for small-moelcule generics).
- The data exclusivity period — the time that must elapse before an SEB can use the data from the reference biologic’s application — is 6 years.
- Studies comparing the reference biologic to the SEB must be conducted in a side-by-side format.
For more information, check out the Ogilvy Renault Pharma in Brief publication, or read the whole Guidance Document.
April 22, 2009
Posted by on
Guest post from Jill Daley, part of our all-star life sciences team at Ogilvy:
Today, Sandoz Canada announced that Health Canada has granted it a market authorization for Omnitrope™.
This announcement marks the approval of the first subsequent entry biologic (SEB, also known as a “follow-on biologic” (FOB) in the U.S. or a “biosimilar” in the EU) of a previously approved recombinant biotechnology drug by Health Canada.
Omnitrope™ has received similar treatment in the United States and in Europe where it has been approved as a “follow-on protein” and a “biosimilar” respectively.
Interestingly, today’s announcement came less than one month following Health Canada’s issuance of the Draft Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics. The Ogilvy Renault bulletin analyzing the draft guidance is here.
The draft guidance is open to consultation until May 26, 2009. Interested stakeholders are invited to submit written coments via email (BGTD_PPD_DPP@HC-SC.GC.CA), mail or fax (613-952-5364).
April 15, 2009
Posted by on
Two Camels! Dolly the cloned sheep, meet Injaz the cloned camel.
Two R&D Heads! The combined Pfizer-Wyeth will have Mikael Dolsten heading up the newly created BioTherapeutics Research Group and Martin Mackay heading up the small molecule PharmaTherapeutics Research Group. (Two CapitalLetters!) The In Vivo Blog has a podcast interviewing both.
Two VA Initiatives! In addition to the electronic medical records initiative we mentioned earlier this week, the Department of Veterans Affairs is also setting up a large cohort genetic study that will establish a database of genetic information from patients that will be linked to the participants’ electronic health records. This is great news for personalized medicine because it will ensure that the EHR standard that comes out of the VA project will accomodate and utilize individualized genotypic data.
Two R’s, Two L’s, Two B’s! G. Steven Burrill (two r’s, two l’s, one b) says he’s confident he can raise $1 billion (there it is!) to develop the Pine Island biotechnology project and a private equity/venture capital fund, which will support development of new technologies out of the Mayo Clinic and the University of Minnesota, among others.
Two Guidance…s! Health Canada issued a finalized version of a Guidance Document on data protection (only applicable to qualifying innovative drugs that received an NOC on or after June 17, 2006) AND a revised version of the draft Guidance Document on Subsequent Entry Biologics, (which includes a 6-year data protection period). More to come on this.
Two Border Crossings! Simponi, a biologic developed by Johnson & Johnson and Schering-Plough, crossed the border Northbound — gaining approval from Health Canada before the FDA; and Molecular Templates Inc. crossed the border Southbound — leaving Ontario for the Texas Life-Sciences Collaboration Center.